Akero Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Akero Therapeutics has a total shareholder equity of $738.3M and total debt of $35.1M, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are $817.5M and $79.2M respectively.
Key information
4.8%
Debt to equity ratio
US$35.12m
Debt
| Interest coverage ratio | n/a |
| Cash | US$717.25m |
| Equity | US$738.33m |
| Total liabilities | US$79.22m |
| Total assets | US$817.55m |
Recent financial health updates
We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04
We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth
Jan 15Recent updates
Akero Therapeutics: Good Candidate For The MASH Basket
Sep 20Akero Therapeutics' EFX Data Warrants Caution
Apr 03Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Mar 04Akero Therapeutics announces closing of upsized public offering
Sep 19Akero adds over 100% rallying peers after NASH success
Sep 13We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth
Jan 15Financial Position Analysis
Short Term Liabilities: AKRO's short term assets ($746.9M) exceed its short term liabilities ($43.3M).
Long Term Liabilities: AKRO's short term assets ($746.9M) exceed its long term liabilities ($35.9M).
Debt to Equity History and Analysis
Debt Level: AKRO has more cash than its total debt.
Reducing Debt: AKRO's debt to equity ratio has increased from 0% to 4.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AKRO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 33.9% each year.